Beam Therapeutics Inc. (BEAM)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow BEAM in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on BEAM and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
BEAM at a glance
Key statistics
$2.57B
Market capitalization
- Previous close
- $24.93
- Open
- $24.83
- Day range
- $24.50 – $25.20
- Volume
- 1.17M
- Average volume (30 sessions)
- 1.79M
- Shares outstanding
- 103.29M
- Earnings per share
- $(0.83)
- Price / book
- 2.4
- Price / sales
- 16.5
- Beta (1 year, vs SPY)
- 2.18
Where the price sits in its year
52-week range
26% of the range
- Below the 52-week high
- -35.1%
- Above the 52-week low
- +22.8%
Completed sessions through Oct 21, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $24.62+0.9%
- 50-day average
- $26.11-4.9%
- 200-day average
- $28.31-12.3%
Between the conventional 30 and 70 bands.
+5.0%
1 week
-4.2%
1 month
-4.1%
3 months
-10.4%
Year to date
-18.9%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with BEAM
BEAM on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on BEAM.
See the plans →
Every planScreen names like BEAM
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on BEAM
Put BEAM on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on BEAM
See whether there is an open premium alert on BEAM, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
BEAM headlines
- Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
GlobeNewswire Inc. · Aug 31, 2026
- Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
GlobeNewswire Inc. · May 18, 2026
- Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
GlobeNewswire Inc. · Mar 25, 2026
- Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
GlobeNewswire Inc. · Feb 24, 2026
- Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
GlobeNewswire Inc. · Feb 23, 2026
- Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc. · Dec 6, 2025
- Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire Inc. · May 29, 2025
- Beam Therapeutics Announces Pricing of Underwritten Offering
GlobeNewswire Inc. · Mar 10, 2025
SEC Form 4, most recent first
Insider filings
Evans John M.
+25.0K
CEO, Director · Option exercise
$25.75K · Oct 15, 2026
Evans John M.
+25.0K
CEO, Director · Option exercise
$25.75K · Oct 16, 2026
Evans John M.
−25.0K
CEO, Director · Open-market sale
$599.60K · Oct 16, 2026
Evans John M.
−25.0K
CEO, Director · Open-market sale
$589.15K · Oct 15, 2026
Evans John M.
−25.0K
CEO, Director · Option exercise
· Oct 16, 2026
Evans John M.
−25.0K
CEO, Director · Option exercise
· Oct 15, 2026
Cavanagh Bethany J
−187
SVP, Finance and Treasurer · Open-market sale
$4.56K · Oct 1, 2026
Ciaramella Giuseppe
−123.4K
President · Gift
· Sep 24, 2026
About Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Employees
- 540
- Listed since
- Feb 6, 2020
- Website
- beamtx.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.